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Abstract 
We have previously shown that treatment of female NOD mice with a potent nonselective histone deacetylase 
inhibitor attenuated experimental autoimmune encephalomyelitis, a model for progressive multiple sclerosis. 
Herein we show that immunization with the MOG35-55 peptide induced prolonged upregulation of genes encod-
ing interleukin 17A (IL-17A), aryl hydrocarbon receptor, and histone deacetylase 11 in the spinal cord whereas 
the subunits of IL-27, IL-27p28 and IL-27ebi3 were significantly increased in secondary lymphoid organs after a 
lag period. Interestingly, the nitric oxide synthase gene was prominently expressed in both of these anatomic 
compartments following immunization. Treatment with the histone modifier repressed the transcription of all 
of these genes induced by immunization. Moreover, the drug suppressed the steady-state levels of the migra-
tion inhibitory factor and CD274 genes in both the spinal cord and peripheral lymphoid tissues. At the same 
time, the CD39 gene was downregulated only in secondary lymphoid organs. Paradoxically, the epigenetic drug 
enhanced the expression of Declin-1 in the spinal cord, suggesting a protective role in neuronal disease. Im-
munization profoundly enhanced transcription of the chemokine CCL2 in the secondary lymphoid tissues with-
out a corresponding increase in the translation of CCL2 protein. Histone hyperacetylation neither altered the 
transcription of CCL2 nor its cognate receptor CCR2 in the central nervous system and peripheral lymphoid 
tissues. Surprisingly, the drug did not exert modulatory influence on most other immune response-related 
genes previously implicated in encephalomyelitis. Nevertheless, our data uncover several potential molecular 
targets for the intervention of experimental autoimmune encephalomyelitis that have implications for the 
treatment of progressive multiple sclerosis. 
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1. Introduction 
Multiple sclerosis (MS), an inflammatory dis-
ease of the central nervous system (CNS), manifests 
commonly as the relapsing-remitting disease. Some 
patients develop primary and secondary progres-
sive forms of disease (Dendrou et al., 2015; Lass-
mann, 2017). The term ‘progressive multiple scle-
rosis’ has been proposed to encompass the primary 
and secondary progressive multiple sclerosis since 
there are more similarities than differences be-
tween them (Fox and Chataway, 2017). Although 
many drugs are effective in reducing relapses, they 
failed to reverse axonal degeneration and are 
sometimes associated with adverse side effects, 
including progressive multifocal leukoencephalopa-
thy (Wingerchuk and Carter, 2014; Tintore et al., 
2019). Thus, effective drugs for the treatment of 
progressive multiple sclerosis remain an unmet 
need. 
Since the early description of the experimental 
autoimmune encephalomyelitis (EAE) in monkeys 
(Rivers et al., 1933), monophasic, self-resolving, 
‘classic’ EAE, as well as ‘atypical’ EAE, have been 
induced in rats and mice using whole spinal cord 
homogenates or peptides derived from the CNS 
components such as myelin oligodendrocyte glyco-
protein (MOG), myelin basic protein (MBP) and 
proteolipid protein (PLP)(Dendrou et al., 2015; 
Lassmann and Bradl, 2017). Autoimmune-prone 
female non-obese diabetic (NOD) mice immunized 
with the MOG35-55 peptide consistently induced 
severe and long-lasting progressive EAE (PEAE) in 
100% of animals characterized by paralysis of fore 
and hind limbs with (Slavin et al., 1998; Hidaka et 
al., 2014; Dang et al., 2015) or without discernible 
remissions (Basso et al., 2008; Jayaraman et al., 
2017; 2018). Regardless, PEAE induced in NOD mice 
mimics features of progressive MS including the 
life-long disease, prominent demyelination, axonal 
loss, and astrogliosis (Slavin et al., 1998; Basso et 
al., 2008; Hidaka et al., 2014; Dang et al., 2015; 
Jayaraman et al., 2017; 2018), and hence is ideal 
for testing the efficacy of new drugs to treat pro-
gressive MS. 
The EAE model is amenable for the investiga-
tion of the genes critically involved in MS patho-
genesis. Previous studies analyzed the roles of vari-
ous immune response-related genes in EAE using 
gene knockout mice and specific neutralizing anti-
bodies in wild-type mice. These studies investigat-
ed the role of T helper 1 (Th1), Th17, and Th1/Th17 
(Th17.1) subsets as well as lymphokines such as 
interferon-γ (IFN- γ) (Ferber et al., 1996; Okuda et 
al., 1998; Hidaka et al., 2014), interleukin-4 (IL-4) 
(Falcone et al., 1998; Okuda et al., 1998; 
Ponomarev et al., 2007), IL-17A (Evangelidou et al., 
2014), IL-10, colony-stimulating factor 1 (Borjini et 
al., 2016), IL-22 (Kreymborg et al., 2007), trans-
forming growth factor-β (TGF-β (Okuda et al., 1998) 
and IL-27 (Li et al., 2005) in EAE. Similarly, the im-
portance of the transcription factors T-bet 
(O’Connor et al., 2013), Gata-3 (Fernando et al., 
2014), and RORγt (Martinez et al., 2014) respective-
ly, involved in the transcription of IFN-γ, IL-4, and 
IL-17A, was also studied in EAE models. Moreover, 
the factors required for the induction of Th1 cells 
such as IL-12 (Gran et al., 2004), IL-18 (Lalor et al., 
2011), and IL-23 (Kreymborg et al., 2007; El-Behi et 
al., 2011) critical for the generation of Th17 cells 
were implicated in EAE. The roles of the pluripotent 
cytokines, namely the tumor necrosis factor-α 
(TNF-α) (Hidaka et al., 2014; Borjini et al., 2016) 
and granulocyte-macrophage-colony-stimulating 
factor (GM-CSF/Csf2) (McQualter et al., 2001) were 
also studied in EAE. In addition to the adaptive 
immune system, the innate immune cells such as 
neutrophils (Jayaraman et al., 2018), and the CNS-
resident microglia and astrocytes (Tran et al., 1997) 
appear to contribute to EAE. Interestingly, the first 
described and phylogenetically conserved pluripo-
tent cytokine, the migration inhibitory factor (MIF) 
(Jayaraman and Muthukkaruppan, 1977), has been 
implicated in MS (Niino et al., 2000) and EAE (Pow-
ell et al., 2005). Other determinants critical for EAE 
include the orphan receptor, aryl hydrocarbon re-
ceptor (Ahr) (Nakahama et al., 2017), the transcrip-
tion factors eomesodermin (Eomes) (Raveney et al., 
2015) and Declin-1 (Dec1/Bhlhe40) (Lin et al., 
2016), the immunoregulatory molecule CD39 (Mas-
canfroni et al., 2013), matrix metalloproteinases 
(MMP) (Kandagaddala et al., 2012; Rempe et al., 
2016), and the chemokine CCL2 (Mahad et al., 
2003; Moreno et al., 2014; Hidaka et al., 2014). The 
caveat is the lack of consensus regarding the critical 
gene(s) involved in EAE. Variations including the 
genetic background of experimental animals (rats 
and mice), types of EAE models studied (short-
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term, self-resolving ‘classic’ EAE, ‘atypical’ EAE, 
relapsing-remitting EAE, and PEAE), the immuno-
gens used for EAE elicitation (whole spinal cord 
homogenates, peptides derived from MOG, MBP 
and PLP), tissues (CNS vs. peripheral lymphoid cells) 
and the time points (peak vs. chronic phase) exam-
ined can contribute to the uncertainty of the re-
sults. Hence, investigation of the roles of these 
various immune response-related genes in a well-
characterized model is likely to yield crucial infor-
mation on the impact of these genes on neuro-
degeneration. 
Our previous work demonstrated that the 
treatment of MOG35-55 immunized female NOD 
mice with the most potent histone deacetylase 
(HDAC) inhibitor Trichostatin A (TSA) (De Ruijter et 
al., 2003) improved the clinical symptoms of PEAE 
(Jayaraman et al., 2017). Protection from PEAE was 
accompanied by histone H3 hyperacetylation in the 
spinal cord (SC) and spleen, reduced influx of T 
cells, and neutrophils into the CNS as well as dimin-
ished axonal damage of the neurons in the CNS 
(Jayaraman et al., 2017; 2018). To gain insights into 
the roles of various genes in the PEAE model, we 
studied the expression profiles of 41 genes encod-
ing lymphokines, transcription factors, accessory 
cell-associated determinants, and chemokines in 
the CNS and secondary lymphoid organs (SLO) lon-
gitudinally during the prolonged course of the dis-
ease (27-weeks). Surprisingly, only a small set of 
mostly non-overlapping genes were differentially 
upregulated in the CNS and SLO, which were sub-
stantially repressed by TSA treatment, indicating 
their possible roles in PEAE. These data suggest 
that similar perturbation of the epigenome of MS 
patients may facilitate the identification of molecu-
lar targets for the development of novel drugs to 
treat this debilitating disease. 
2. Material and methods 
2.1. EAE induction and treatment 
This study was approved by the Institutional 
Animal Care and Use Committee of The University 
of Illinois at Chicago and conducted according to 
the National Institutes of Health guide for the care 
and use of Laboratory Animals (NIH Publications 
No. 8023, revised 1978). Female NOD/ShiLtj mice 
were purchased from The Jackson Laboratories (Bar 
Harbor, ME) and immunized subcutaneously (s.c) 
on the flank with 100 µg of mouse MOG35-55 pep-
tide (Tocris Bioscience) emulsified in complete 
Freund's adjuvant and pertussis toxin was adminis-
tered intravenously (Jayaraman et al., 2017; 2018). 
Randomly chosen littermates were injected s.c on 
the flank with 500 µg of TSA (Sigma Chemical Com-
pany, St. Louis, MO) per Kg body weight three 
times a week. Controls received the same amount 
of the vehicle, dimethyl sulfoxide (DMSO) (Sigma) 
diluted in phosphate-buffered saline (PBS). The 
body weight, blood glucose levels, (Jayaraman et 
al., 2010; 2013; Jayaraman and Jayaraman, 2018; 
Patel et al., 2011) and clinical scores (Jayaraman et 
al., 2017; 2018) were recorded three times a week. 
The EAE score was assigned as follows: 0, healthy, 
1, limp tail, 2, one hind limb weakness, 3, both hind 
limb weakness, 4, forelimb weakness, 5, paralysis, 
moribund or death (Jayaraman et al., 2017; 2018). 
Five mice per group were chosen based on our 
previous investigations (Jayaraman et al., 2017; 
2018). The data are presented as the mean ± SEM 
for each time point of observation. 
2.2. Gene expression analysis 
We analyzed the expression levels of 41 genes 
in the entire SC and SLO (spleen and the draining 
inguinal, popliteal, axillary and cervical lymph 
nodes) of mice that were immunized with MOG35-55 
and treated with DMSO or TSA. We have investi-
gated 60 mice (five mice treated with DMSO and 
five mice with TSA at six-time points) for the ex-
pression of genes in the SC and SLO concurrently. 
To analyze the effect of the drug on the basal level 
of gene transcription regardless of immunization, 
we treated separate groups of 10 unimmunized 
mice with TSA or DMSO and analyzed one day later 
since TSA acts within hours of treatment (Van Lint 
et al., 1996; De Ruijter et al., 2003). These data are 
indicated at the day 1-time point in all figures. On 
the other hand, treatment groups received DMSO 
or TSA starting from the day of immunization. Mice 
were perfused with PBS before the spinal cord was 
extracted to avoid peripheral blood contamination 
(Jayaraman et al., 2017; 2018). Total RNA was iso-
lated from individual mice using TRIzol (Invitrogen, 
Carlsbad, CA). Since preliminary experiments indi-
cated similar levels of expression of genes among 
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different mice in each group, the RNA from five 
mice per group at each time point was pooled from 
identical tissues to minimize individual variability, 
as described previously (Jayaraman et al., 2013). 
The RNA was treated with Turbo DNase and con-
verted to cDNA using the High-Capacity cDNA Re-
verse Transcription kit (Applied Biosystems, Carls-
bad, CA), as described earlier (Jayaraman et al., 
2010; 2013; 2017; 2018; Patel et al., 2011). Real-
time quantitative reverse-transcriptase mediated 
polymerase chain reaction (qRT-PCR) was per-
formed using the Applied Biosystems ViiA7 Real-
time PCR system. The cDNA equivalent to 100 ng of 
total RNA was used along with the 2X SYBR Green 
master mix in the qRT-PCR assay. The primer sets 
were designed, and specificity validated using the 
Primer3 and BLAST programs (ncbi.nim.nih.gov) 
and BiSearch Web Server tool (bisearch.enzim.hu). 
The Mif primer sets were purchased from the Inte-
grated DNA Technologies (Coralville, IA), and the 
custom primers were synthesized at the same facil-
ity. Whereas the primer sets for Gapdh, Il4, Il17a, 
Il18, Ifng, Nos2, Tnfa, Tbet, Rorgt, and Gata3 were 
described previously (Jayaraman et al., 2010; 
2013), other primer sets are listed in Supplemen-
tary Table 1. Every cDNA sample was analyzed in 
triplicate at each time point, and the expression 
level of any given gene was ascertained using 
Gapdh as the normalizer (Jayaraman et al., 2010; 
2013; 2017; 2018; Patel et al., 2011) since it was 
not altered by TSA treatment in vitro (Van Lint et 
al., 1996). The same cDNA pool was analyzed for 
the expression levels of all 41 genes. The gene ex-
pression level was determined using the 2-∆∆CT 
method (Jayaraman et al., 2010; 2013; 2017; 2018; 
Patel et al., 2011). The data are represented as the 
mean ± SEM of triplicate technical repeats per time 
point. The outliers that deviated >10% from other 
data points were omitted, and the samples reana-
lyzed for gene expression. 
2.3. ELISA 
Sera were collected from naïve and immun-
ized mice with or without TSA treatment and as-
sayed for CCL2 using the ELISA Ready-SET-Go kit 
(eBioscience, San Diego, CA). Samples were pooled 
from five mice per group, analyzed in duplicate, 
and expressed per mg of protein. 
2.4. Statistics 
The statistical significance of clinical scores be-
tween control and TSA-treated groups was deter-
mined using the area under the ROC curve. The 
difference in gene expression was calculated using 
an unpaired two-tailed Student's t-test. ELISA data 
were analyzed for significance between groups by 
two-way ANOVA. The P-value of <0.05 was consid-
ered significant. GraphPad Prism 6.0 software (San 
Diego, CA) was used for all statistical analyses. 
3. Results 
3.1. TSA treatment reduced the clinical manifes-
tation of PEAE 
We have reported earlier that after immuniza-
tion with the MOG35-55 peptide the bodyweight 
declined transiently between 13 and 16 days, which 
steadily increased after that regardless of treat-
ment with DMSO or TSA (Jayaraman et al., 2017). 
Since female NOD mice develop type 1 diabetes in 
an age-dependent manner, we routinely monitored 
blood glucose levels three times a week throughout 
the experiments. As reported earlier (Jayaraman et 
al., 2010; 2013; Jayaraman and Jayaraman, 2018; 
Patel et al., 2011), mice that were 9-11 weeks old 
(Fig. 1A, D-E) were normoglycemic at the time of 
immunization with MOG35-55 emulsified in complete 
Freund’s adjuvant and remained diabetes-free 
throughout the observation, 12-27 weeks of age 
(Fig. 1A, D-E). However, in two experiments, 40 and 
60% of 17-week old mice immunized and treated 
with DMSO were found to be diabetic. TSA treat-
ment reduced the diabetes incidence respectively 
to 0% and 20% when analyzed at 20 and 21 weeks 
of age (Fig. 1B-C). These results are consistent with 
our previous observations that the administration 
of complete Freund’s adjuvant alone could effec-
tively prevent type 1 diabetes in younger female 
NOD mice. In contrast, similar treatment of older 
(>13-weeks) mice did not have the same potency in 
preventing diabetes (Jayaraman and Jayaraman, 
2018). These results indicate that whereas the de-
velopment of type 1 diabetes is age-dependent, 
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Fig. 1 TSA treatment improved clinical disease. 
Randomly chosen littermates of female NOD mice were immunized with MOG35-55 and treated with TSA or DMSO three times a week for 
the indicated time interval. Clinical scores of five mice/group were determined on indicated time intervals and depicted as mean ± SEM. 
The statistical significance between DMSO (blank bars) and TSA-treated mice (hatched bars) was determined using the area under the 
ROC curve test and indicated. Individual data for DMSO (empty circles) and TSA-treated (empty squares) groups are also indicated. Mice 
were killed on day 14 (A), 21 (B), 28 (C), 54 (D), and 115 (E), and their spinal cord and peripheral lymphoid tissues were harvested and 
used for gene expression analysis. 
 
induction of PEAE by immunization with the MOG35-
55 peptide emulsified in complete Freund’s adjuvant 
is independent of the age and the glycemic status 
of mice. 
All of the mice immunized with MOG35-55 de-
veloped PEAE without discernible remission (Fig. 
1A-E), consistent with earlier reports (Basso et al., 
2008; Jayaraman et al., 2017; 2018). The overall 
clinical severity was comparable in most instances 
except in a single experiment, probably due to the 
difference in experimental conditions (Fig. 1C). 
Treatment with TSA bestowed robust and irreversi-
ble protection from PEAE for the entire period of 
observation (115 days) even after the cessation of 
the drug administration on day 45 (Fig. 1E), as re-
ported earlier (Jayaraman et al., 2017). Interesting-
ly, the administration of the drug for one (Fig. 1A), 
two (Fig. 1B, C), four (Fig. 1D) or six-weeks (Fig. 1E) 
afforded a comparable level of protection against 
the disease. In previous studies, we have demon-
strated that chronic TSA treatment decreased the 
influx of neutrophils and CD4+ T cells into the SC. 
Drug treatment also reduced the inflammation and 
particularly axonal damage in the spinal cord, indi-
cating the neuroprotective effect of the HDAC in-
hibitor (Jayaraman et al., 2017; 2018). To under-
stand the underlying mechanisms of drug-mediated 
protection against PEAE, in the current study, we 
have concurrently profiled the gene expression in 
the CNS and SLO at various time points shown in 
Fig. 1A-E. 
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Fig. 2 Differential impact of the histone modifier on gene expression in the CNS. 
Total RNA was extracted individually from five mice per group from the spinal cord (SC) at various time points. At each time point, RNA 
pooled from five mice/group was analyzed in triplicate. The expression of indicated genes was normalized to the housekeeping gene, 
Gapdh, and depicted as mean ± SEM of triplicate samples. Statistical significance (P<0.05) between DMSO (blank bars) and drug-treated 
mice (hatched bars) was determined using an unpaired two-tailed t-test and indicated by asterisks. Individual replicates for DMSO 
(empty circles) and TSA-treated samples (empty squares) are also shown. Unimmunized mice (10/group) were treated with DMSO or 
TSA and analyzed one day later for the effect of drug treatment on the basal level expression of genes irrespective of immunization. 
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3.2. Differential impact of the histone modifier 
on gene expression in the CNS 
The neuronal disease induced in NOD mice re-
sembled the ‘classic’ EAE except that it lasted long-
er than in most strains of mice (Slavin et al., 1998; 
Basso et al., 2008; Hidaka et al., 2014; Dang et al., 
2015; Jayaraman et al., 2017; 2018). Since the SC is 
thought to be the primary target of the ‘classic’ EAE 
and the brain damage was selectively observed in 
'atypical’ EAE (Pierson and Goverman, 2017), we 
profiled the gene expression in the entire SC. Ex-
pression levels of genes encoding 11 lymphokines, 
four cytokines, seven accessory cell surface-
associated determinants, seven transcription fac-
tors, and 11 histone deacetylases (Hdacs) were 
investigated by qRT-PCR. Unimmunized mice were 
separately treated with DMSO or TSA to determine 
the impact of drug treatment on the constitutive 
level of gene expression. The data are indicated at 
the day-1 time point in all figures. Mice immunized 
with MOG35-55 were treated with DMSO or TSA 
starting from the day of immunization. The entire 
data sets are presented in Supplementary Fig. 1-5. 
Only the differences in gene expression that occur 
consecutively at more than one-time point but not 
those altered transiently or sporadically are high-
lighted herein. 
Longitudinal analysis during chronic PEAE re-
vealed that some immune response-related genes 
were induced upon MOG35-55 immunization after a 
7-14-day lag period in both the CNS and SLO. The 
Th cell-associated Il17a, Il4, and Il22 and the in-
flammatory cytokine gene Nos2 were upregulated 
for a prolonged period between 21 and 54 days in 
the CNS in different experiments (Fig. 2A-D). The 
epigenetic drug suppressed the expression of these 
genes that were upregulated by immunization. 
Surprisingly, the constitutive expression of Mif, Ahr, 
and Cd274 was also notably repressed by TSA 
treatment during the chronic phase of the disease 
(Fig. 2E-G). Unexpectedly, the pan HDAC inhibitor 
upregulated the expression of Dec1 (Bhlhe40), spe-
cifically during the late stage of PEAE (Fig. 2H). 
 
Although previous studies implicated many 
other genes in EAE, those encoding IL-23, IFN-γ, IL-
18, IL-27p28, IL-27ebi3, IL-12p35, IL-10, GM-CSF, 
TNF-α, and TGF-β were not transcriptionally upreg-
ulated in the CNS of PEAE mice (see Supplementary 
Fig. 1-2). Similarly, the mRNA of the accessory cell 
surface-associated determinants, MMP9, MMP12, 
and CD74, remained stable in the CNS following 
immunization (Supplementary Fig. 3). Moreover, 
the transcription factor genes such as Tbet, Gata3, 
Rorgt, Eomes, and Foxp3 also remained unchanged 
in the SC (Supplementary Fig. 4). Notably, the his-
tone modifier failed to alter the transcription of 
these genes. Thus, our comprehensive analysis 
uncovered the selective repression of genes in the 
CNS without affecting the levels of many other 
genes previously implicated in neuroinflammation. 
3.3. The different patterns of gene regulation in 
the SLO by TSA treatment 
The expression of the genes encoding the 
subunits of the heterodimeric lymphokine IL-27 
such as IL-27p28 and IL-27ebi3 peaked on day 21 
and subsided steadily thereafter in the SLO (Fig. 3A-
B). Treatment with TSA reduced the expression of 
these genes and the inflammatory gene Nos2 (Fig. 
3C). Interestingly, the transcription of Mif, Cd274, 
and Cd39 in the SLO was also downregulated by the 
histone modifier (Fig. 3D-F). Surprisingly, the genes 
encoding the lymphokines such as IL-4, IL-10, IL-
17A, IL-12p35, IL-18, IL-22, IL-23, IFN-γ, TGFβ, GM-
CSF and TNF-α (Supplementary Fig. 1-2), as well as 
the macrophage-associated determinants, MMP9, 
MMP12, Arg-1, and CD74 were neither upregulated 
during pathogenesis nor repressed by TSA treat-
ment in the SLO (Supplementary Fig. 3). Similarly, 
the transcription of Tbet, Rorgt, Gata3, Eomes, 
Dec1, Ahr, and Foxp3 remained mostly unaffected 
by the HDAC inhibitor treatment (Supplementary 
Fig. 4). Thus, the antigen-induced transcription of 
Il27p28, Il27ebi3, and Nos2, as well as the constitu-
tive expression of Mif, Cd274, and Cd39, were se-
lectively impeded by TSA treatment in the SLO. 
These data collectively demonstrate the differential 
influence of epigenetic modulation on gene expres-
sion in the CNS and SLO in the PEAE model. 
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Fig. 3 Different patterns of gene regulation in the SLO by TSA treatment. 
Expression levels of indicated genes were determined in control DMSO (blank bars) and TSA-treated mice (hatched bars) using the total 
RNA derived from the spleen and draining lymph nodes (SP) from individual mice at the indicated time points. At each time point, RNA 
pooled from five mice/group was analyzed in triplicate. Individual data points for DMSO (empty circles) and TSA-treated (empty 
squares) are shown. Gene expression was normalized to the housekeeping gene, Gapdh, and depicted as mean ± SEM of triplicate sam-
ples. Statistical significance (P<0.05) between control and drug-treated mice was determined using an unpaired two-tailed t-test and 
indicated by asterisks. Unimmunized mice (10/group) were treated with DMSO or TSA and analyzed one day later for the effect of drug 
treatment on the basal level expression of genes irrespective of immunization. 
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3.4. Epigenetic regulation failed to influence the 
prominent chemokine system 
Since previous work indicated the nonredundant 
roles of CCL2 and CCR2 in recruiting the inflamma-
tory cells to the CNS (Mahad and Ransohoff, 2003; 
Moreno et al., 2014), we surmised that TSA-
induced neuroprotection could also accompany 
modulation of these genes. Immunization of NOD 
mice with MOG35-55 did not transcriptionally upreg-
ulate Ccl2 in the CNS (Fig. 4A). On the other hand, 
Ccl2 transcription increased dramatically in the SLO 
between days 14 and 28 (Fig. 4B). However, TSA 
treatment failed to modulate the transcription of 
Ccl2 in the SC or SLO. The gene encoding the cog-
nate receptor of CCL2, CCR2, was not distinctively 
upregulated in either the SC or SLO nor perturbed 
by the histone modifier (Fig. 4C-D). In contrast to 
the robust increase in the Ccl2 mRNA level in the 
SLO, the amount of CCL2 protein did not increase in 
circulation during the pre-symptomatic period (up 
to 16 days) as assessed by ELISA, which remained 
unaffected by TSA treatment (Fig. 4E). These data 
indicate that protection from PEAE afforded by the 
CNS-permeant TSA (Jayaraman et al., 2017; 2018) 
was not associated with the transcriptional regula-
tion of the prominent chemokine system, CCL2: 
CCR2 either in the CNS or SLO. 
3.5. TSA treatment repressed the transcription 
of Hdac11 selectively in the CNS 
Whereas TSA can inhibit the activity of HDAC 
class I, IIa, and IIb isoenzymes with varying potency 
in vitro (Bradner et al., 2010), its ability to regulate 
Hdac genes in vivo has not been determined.
 
 
 
Fig. 4 Epigenetic regulation failed to influence the prominent chemokine system. 
Expression levels of indicated genes were determined in DMSO (blank bars) and TSA-treated mice (hatched bars) using the total RNA 
derived from the spinal cord (SC) (A, C) and peripheral lymphoid tissues (SP) (B, D) at various time points. At each time point, RNA was 
extracted from five individual mice/group, pooled, and analyzed in triplicate. Gene expression was normalized to the housekeeping 
gene, Gapdh, and depicted as mean ± SEM of triplicate samples. Individual data points are shown for DMSO (blank circles) and TSA-
treated (empty squares) groups. CCL2 protein was estimated in duplicate from pooled sera of five mice per group using ELISA (E). 
Unimmunized mice (10/group) were treated with DMSO or TSA and analyzed one day later for the effect of drug treatment on the basal 
level expression of genes irrespective of immunization. Statistical significance (P<0.05) between control and drug-treated mice 
(n=five/group) was determined using an unpaired two-tailed t-test and indicated by asterisks. 
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To address this issue, we analyzed the mRNA levels 
of class I (Hdac1, Hdac2, Hdac3, and Hdac8), class 
IIa (Hdac4, Hdac5, Hdac7, and Hdac9), class IIb 
(Hdac6 and Hdac10), and class IV (Hdac11) HDACs 
using validated primer sets and qRT-PCR. Data 
shown in Fig. 5 indicate that immunization of NOD 
mice with MOG35-55 steadily increased the tran-
scription of the class IV Hdac11 in the SC, which 
remained at high levels between 21 and 54 days 
postimmunization. Importantly, TSA treatment 
reduced the transcript level of Hdac11. Although 
Hdac1, Hdac4, Hdac5, Hdac6, Hdac8, and Hdac9 
were modestly increased in the CNS with different 
kinetics after immunization, they were relatively 
insensitive to TSA treatment. Surprisingly, the ex-
pression levels of HDAC genes, including the 
Hdac11, did not increase significantly in the SLO of 
MOG35-55 immunized mice nor repressed by TSA 
treatment (Supplementary Fig. 5). These results 
indicate that MOG35-55 immunization leads to in-
creased transcription of Hdac11 in a CNS-specific 
fashion, which is rendered sensitive to the action of 
the histone modifier. These results indicate the 
possibility that Hdac11 could represent a novel 
target for the manipulation of PEAE. 
 
 
 
Fig. 5 TSA treatment repressed the transcription of Hdac11 selectively in the CNS. 
Expression levels of indicated Hdac genes were determined in DMSO (blank bars) and TSA-treated mice (hatched bars) in the spinal cord 
as shown. At each time point, RNA was isolated from five individual mice/group, pooled and analyzed in triplicate. Gene expression was 
normalized to the housekeeping gene Gapdh and depicted as mean ± SEM of triplicate samples. Individual data points are shown for 
DMSO (blank circles) and TSA-treated (empty squares) groups. Statistical significance (P<0.05) between control and the drug-treated 
group was determined using an unpaired two-tailed t-test and indicated by asterisks. ns, not significant. Unimmunized mice (10/group) 
were treated with DMSO or TSA and analyzed one day later for the effect of drug treatment on the basal level expression of genes irre-
spective of immunization. 
Free Neuropathology 1:19 (2020) Arathi K. Jayaraman et al 
doi: https://doi.org/10.17879/freeneuropathology-2020-2819 page 11 of 16 
 
 
 
4. Discussion 
A cardinal assumption has been that the T 
lymphocytes play a crucial role in the induction and 
manifestation of multiple sclerosis, and therefore, 
induction of antigen-specific T cell tolerance is a 
reasonable approach to treat this debilitating dis-
ease. Many attempts, including immunization with 
various neuronal peptides and T cell vaccinations, 
have failed to induce T cell tolerance and amelio-
rate multiple sclerosis symptoms (Wingerchuk and 
Carter, 2014; Dendrou et al., 2015; Steinman, 2015; 
Lassmann, 2017). However, the induction of anti-
gen-specific T cell tolerance using immunomodula-
tory drugs remains unexplored in patients with MS 
and other autoimmune disorders.  
Recently, we have demonstrated that treat-
ment with the potent HDAC inhibitor TSA not only 
reduced the frequencies of Th1, Th17, and 
Th1/Th17 cells in the SLO and their influx into the 
CNS but also induced MOG35-55 peptide-specific T 
cell tolerance (anergy) in NOD mice (Jayaraman et 
al., 2017). Although anergy was originally reported 
in a mouse Th1 clone that was suboptimally acti-
vated without co-stimulation in vitro (Schwartz et 
al., 1989; Jayaraman et al., 1992), the underlying 
mechanisms have not been fully deciphered. Our 
investigation unraveled a good correlation between 
TSA-mediated neuroprotection and downregula-
tion of selected immune response-related genes 
both in the CNS and SLO. Whereas these data may 
not directly impinge upon histone modifier-
facilitated MOG35-55 peptide-specific T cell toler-
ance, they highlight the possible impact of differen-
tial gene expression on PEAE. 
The epigenetic approach unraveled an inverse 
relationship between the expression levels of a 
small set of genes and neuroprotection. In the CNS 
of PEAE NOD mice, Il17a expression was upregulat-
ed for over a month (Fig. 2), unlike its expression at 
the peak of the monophasic EAE (Kreymborg et al., 
2007; Evangelidou et al., 2014; Borjini et al., 2016). 
Prolonged expression of Nos2 in the CNS (Fig. 2B) is 
congruent with the association of iNOS-positive 
macrophages and glial cells in demyelinating pa-
thology (Tran et al., 1997). In addition to the Nos2 
(Fig. 3C), the subunits of IL-27, namely IL-27p28, 
and IL-27EBi3, were prominently upregulated at 
the mRNA level in the SLO (Fig. 3B-C). This is con-
sistent with an encephalitogenic role of IL-27 sug-
gested by the suppression of the ongoing EAE fol-
lowing administration of the neutralizing antibody 
against the IL-27p28 subunit (Goldberg et al., 
2004). Besides, TSA treatment reduced the steady-
state expression of Mif in both the CNS and SLO 
(Fig. 2E, Fig. 3E), consistent with a proposed patho-
genic role of MIF in monophasic EAE (Powell et al., 
2005). We have previously shown that TSA treat-
ment diminished the numbers of splenocytes ex-
pressing the co-inhibitory ligand CD274 (PD-L1) 
(Jayaraman et al., 2018). Consistently, the Cd274 
mRNA level was also repressed in the CNS (Fig. 2G) 
and SLO (Fig. 3F) of TSA-treated PEAE mice, sug-
gesting a role for this co-inhibitory ligand in en-
cephalomyelitis, as proposed (Jayaraman et al., 
2018). Also, the expression of Ahr, uniquely re-
quired for the generation of T cells responsible for 
the late-onset EAE (Nakahama et al., 2013) was 
diminished in mice protected by TSA treatment 
(Fig. 2F). Collectively, the TSA-mediated downregu-
lation of both inducible and constitutively ex-
pressed genes appears to be inversely proportional 
to the severity of the neuronal disease. However, it 
remains to be determined whether the expression 
levels of these genes may serve as biomarkers for 
the diagnosis of MS. Nevertheless, the information 
uncovered in the NOD mouse model may provide a 
framework for potential MS treatment, typically 
diagnosed as clinically isolated syndrome followed 
by years of asymptomatic period (Dendrou et al., 
2015). 
The upregulation of the transcription of 
Hdac11 in a CNS-specific fashion in mice immun-
ized with MOG35-55 (Fig. 5) represents the first re-
port of differential expression of Hdac genes in 
vivo. Although the non-selective HDAC inhibitor 
TSA did not diminish the HDAC11 enzymatic activity 
in vitro (Bradner et al., 2010), our data demon-
strated the control of Hdac11 by TSA at the tran-
scriptional level. Since Hdac11 gene expression was 
determined in the SC devoid of peripheral blood 
contamination, its reduction appears to be a direct 
effect of TSA on the CNS resident cells. Although 
we have not identified the cellular source of 
Hdac11 in the spinal cord, previous work suggested 
that Hdac11 knockdown increased Il10 expression 
in peripheral antigen-presenting cells resulting in 
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immunosuppression in vitro (Villagra et al., 2009). 
In contrast, TSA-induced tolerance in MOG35-55-
specific T lymphocytes (Jayaraman et al., 2017) did 
not accompany the upregulated transcription of 
Il10 in the CNS or SLO (see Supplementary Fig. 1). 
Although the deletion of Hdac1 selectively in T cells 
was reported to prevent EAE (Göschl et al., 2018), 
immunization with MOG35-55 neither upregulated 
the expression of this gene, nor the epigenetic drug 
influenced its transcription in the SLO or CNS (Fig. 
5, Supplementary Fig. 5). Thus, the histone hyper-
acetylating drug appears to primarily target the 
Hdac11 gene in the CNS of PEAE mice and the elu-
cidation of the genes that are under the control of 
Hdac11 may provide novel insights into the mecha-
nisms of PEAE.  
To our surprise, the epigenetic drug treatment 
failed to validate the purported roles of the genes 
critical for the development of encephalitogenic 
Th1 and Th17 subsets, including Ifng, Il12, Il18, Il23, 
Tbet, Rorgt, Gata3, and Eomes. The disruption of 
the IFN-γ gene failed to influence EAE development 
(Ferber et al., 1995), indicating a lack of IFN-γ-
expressing cells in neurodegeneration. Consistent-
ly, the reduction of clinical symptoms by TSA 
treatment did not accompany the transcriptional 
repression of IFN-γ (Supplementary Fig. 1). Besides, 
the drug-mediated tolerance induction was evident 
without repressed transcription of Tbet, Il18, and 
Il12 genes critical for Th1 cell development (O'Con-
nor et al., 2013; Lalor et al., 2011; Gran et al., 2004) 
(see Supplementary Fig. 3). Moreover, the tran-
scription of Il23 (Kreymborg et al., 2007; El-Behi et 
al., 2011) and Rorgt (Martinez et al., 2014), respec-
tively, involved in Th17 and Th2 cell generation was 
also not diminished by TSA treatment. Yet, the his-
tone modifier reduced the overall numbers of Th17 
and Th1/Th17 cells in the SLO (Jayaraman et al., 
2017). Furthermore, the drug treatment failed to 
decrease the transcription of Csf2 (see Supplemen-
tary Fig. 2) despite the diminished numbers of GM-
CSF-co-expressing Th1 and Th17 cells found in the 
SLO of TSA-treated mice (Jayaraman et al., 2017). 
These data indicate that T cell tolerance induction 
by epigenetic modulation of the genome does not 
involve selective suppression of genes required for 
the generation of functionally distinct Th cell sub-
sets. Further work is necessary to decipher the 
underlying mechanisms of T cell tolerance.  
Another deviation from the conventional idea 
of immunoregulation is the lack of the modulation 
of Il10 and Foxp3 both in the CNS and SLO of TSA-
treated mice (Supplementary Fig. 4). Although 
Foxp3+ T regulatory cells are considered critical for 
immunoregulation (Hori et al., 2003), their role in 
EAE is less compelling (Jayaraman et al., 2017; 
Danikowski et al., 2017; Jayaraman and Prabhakar, 
2019). Whereas TSA treatment increased Foxp3 
expression and promoted T regulatory cell function 
via the upregulation of Hdac9 in a different exper-
imental model (Tao et al., 2007), our results con-
tradict these findings. It is also noteworthy that TSA 
treatment downregulated Foxp3 expression and 
lowered the numbers of CD4+CD25+ T regulatory 
cells (Liu et al., 2010). Nevertheless, our data indi-
cate that TSA-mediated protection from PEAE in 
autoimmune-prone NOD mice is independent of IL-
10 and Foxp3+ T regulatory cells.  
Differential RNA display (Van Lint et al., 1996) 
and microarray analysis of gene expression (Jaya-
raman et al., 2013) indicated that histone hyper-
acetylation by TSA treatment could have positive, 
negative, or no effect on gene transcription. Our 
qRT-PCR analysis showed that out of 41 genes in-
terrogated, 11 were consistently downregulated 
over multiple time points following TSA treatment 
(vide supra). Rarely, TSA treatment can also in-
crease the transcription of genes due to the tran-
scriptional suppression of repressor complexes that 
control gene expression. Thus, Dec1 was selectively 
upregulated in the CNS by the histone modifier, 
suggesting a role in protection against PEAE (Fig. 
2H). This is in contrast to the finding that the genet-
ic deletion of Dec1 (Bhlhe40-/-) afforded resistance 
to EAE induction (Lin et al., 2016). Like an earlier 
study (Hidaka et al., 2014), we found that the ex-
pression of the CCL2 gene was dramatically in-
creased in the SLO of MOG35-55 immunized NOD 
mice (Fig. 4). However, TSA treatment failed to 
influence its expression. Moreover, there is a dis-
connect between the CCL2 mRNA expression in the 
SLO and the release of the CCL2 protein into the 
peripheral blood. It has been proposed that CCL2 
expressed by the CNS resident astrocytes may 
serve as a target for MS treatment (Mahad and 
Ronsohoff, 2003; Moreno et al., 2014). However, 
Ccl2 and Ccr2 genes are refractory to histone hy-
peracetylation, and therefore do not appear to be 
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essential for PEAE induction and manifestation. 
This observation does not come as a surprise since 
the level of CCL2 was also reported to be lower in 
relapsing-remitting MS patients (Narikawa et al., 
2004; Moreira et al., 2006), and the IFN-beta 1a 
therapy reduced relapses while increasing the level 
of CCL2 in MS patients (Szczuciński and Losy, 2004). 
Thus, these data do not support the hypothesis 
that the CCL2: CCR2 system may impact neuro-
degeneration.  
It is noteworthy that TSA administration in-
duced neuroprotection and gene regulation similar-
ly in prediabetic, 9-13 weeks old, and aged (17-
weeks old) mice (Jayaraman et al., 2017; Fig. 1-5). 
The administration of the epigenetic drug for one 
to six weeks bestowed comparable neuroprotec-
tion and gene regulation irrespective of the age of 
the mice. Circumstantial evidence also indicates the 
lack of influence of diabetes on PEAE induction. As 
expected, the prediabetic (9-13-weeks old) mice 
were normoglycemic at the time of immunization 
with MOG35-55 and remained non-diabetic as long 
as 27 weeks of age. The lack of diabetes in immun-
ized mice could be due to the action of the micro-
bial products present in the complete Freund’s 
adjuvant. In fact, we have shown that the admin-
istration of complete Freund’s adjuvant alone is 
sufficient to prevent prediabetic NOD mice from 
developing overt diabetes (Jayaraman and Jayara-
man, 2018). Although a fraction of the older (17 
weeks old) mice developed diabetes, it did not 
impede PEAE induction (Fig. 1B-C) nor the modula-
tion of gene expression in response to TSA treat-
ment (Fig. 2-5). Collectively, these data demon-
strate that the induction of PEAE and epigenetic 
regulation of gene expression is unrelated to the 
age or the glycemic status of mice. 
Conclusions 
The analysis of the 41 genes using qRT-PCR 
unraveled differential regulation of gene expres-
sion in the CNS and SLO by an epigenetic drug. This 
study has highlighted the roles of Il4, Hdac11, 
Cd274, and Cd39 in the CNS in addition to validat-
ing previously implicated genes, Il17a, Il22, iNos, 
Ahr, and Mif in neuroinflammation. On the other 
hand, in the SLO, the roles of Il22, Il27, Nos2, and 
Mif were confirmed while indicating the participa-
tion of Cd274 and Cd39 in PEAE. Some of these 
genes are induced by immunization, while others 
are constitutively expressed. Surprisingly, many 
other genes previously implicated in EAE were re-
fractory to histone hyperacetylation mediated 
transcriptional regulation. Hence, it will be difficult 
to conclude whether these genes do not contribute 
to neuroinflammation. Nevertheless, our data sug-
gest that the drug-induced histone hyperacetyla-
tion is a promising strategy to treat demyelination 
and axonal damage by modifying the expression of 
selected genes. Although the therapeutic potential 
of HDAC inhibitors for the treatment of multiple 
sclerosis has been entertained (Faraco et al., 2011), 
direct evidence is lacking (Göbel et al., 2018). The 
data generated in the NOD mouse model provide a 
framework for a similar pharmacological approach 
to treat MS patients. 
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